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Abstract: Context: Catecholamines and adrenocortical steroids are important regulators of blood pres-
sure. Bidirectional relationships between adrenal steroids and catecholamines have been established but
whether this is relevant to patients with pheochromocytoma is unclear. Objective: This study addresses
the hypothesis that patients with pheochromocytoma and paraganglioma (PPGL) have altered steroid
production compared to primary hypertensives. Design: Multicenter cross-sectional study. Setting:
Twelve European referral centers. Patients: Subjects included 182 patients with pheochromocytoma,
36 with paraganglioma and 270 primary hypertensives. Patients with primary aldosteronism (n=461)
and Cushing syndrome (n=124) were included for additional comparisons. Intervention: In patients with
PPGLs, surgical resection of tumors. Outcome measures: Differences in mass spectrometry-based profiles
of 15 adrenal steroids between groups and after surgical resection of PPGLs. Relationships of steroids to
plasma and urinary metanephrines and urinary catecholamines. Results: Patients with pheochromocy-
toma had higher (P<0.05) circulating concentrations of cortisol, 11-deoxycortisol, 11-deoxycorticosterone
and corticosterone than primary hypertensives. Concentrations of cortisol, 11-deoxycortisol and corticos-
terone were also higher (P<0.05) in patients with pheochromocytoma than with paraganglioma. These
steroids correlated positively with plasma and urinary metanephrines and catecholamines in patients
with pheochromocytoma, but not paraganglioma. After adrenalectomy, there were significant decreases
in cortisol, 11-deoxycortisol, corticosterone, 11-deoxycorticosterone, aldosterone and 18-oxocortisol. Con-
clusions: This is the first large study in patients with PPGLs that supports in a clinical setting the concept
of adrenal cortical-medullary interactions involving an influence of catecholamines on adrenal steroids.
These findings could have implications for the cardiovascular complications of PPGLs and the clinical
management of patients with the tumors.
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Context: Catecholamines and adrenocortical steroids are important regulators of blood pressure. 
Bidirectional relationships between adrenal steroids and catecholamines have been established but 
whether this is relevant to patients with pheochromocytoma is unclear. 
Objective: This study addresses the hypothesis that patients with pheochromocytoma and 
paraganglioma (PPGL) have altered steroid production compared to primary hypertensives.  
Design: Multicenter cross-sectional study 
Setting: Twelve European referral centers 
Patients: Subjects included 182 patients with pheochromocytoma, 36 with paraganglioma and 270 
primary hypertensives. Patients with primary aldosteronism (n=461) and Cushing syndrome (n=124) 
were included for additional comparisons.  
Intervention: In patients with PPGLs, surgical resection of tumors. 
Outcome measures: Differences in mass spectrometry-based profiles of 15 adrenal steroids between 
groups and after surgical resection of PPGLs. Relationships of steroids to plasma and urinary 




























































































Results: Patients with pheochromocytoma had higher (P<0.05) circulating concentrations of cortisol, 
11-deoxycortisol, 11-deoxycorticosterone and corticosterone than primary hypertensives. 
Concentrations of cortisol, 11-deoxycortisol and corticosterone were also higher (P<0.05) in patients 
with pheochromocytoma than with paraganglioma. These steroids correlated positively with plasma 
and urinary metanephrines and catecholamines in patients with pheochromocytoma, but not 
paraganglioma. After adrenalectomy, there were significant decreases in cortisol, 11-deoxycortisol, 
corticosterone, 11-deoxycorticosterone, aldosterone and 18-oxocortisol.  
Conclusions: This is the first large study in patients with PPGLs that supports in a clinical setting the 
concept of adrenal cortical-medullary interactions involving an influence of catecholamines on 
adrenal steroids. These findings could have implications for the cardiovascular complications of 
PPGLs and the clinical management of patients with the tumors. 






























































































Pheochromocytoma is a tumor arising from chromaffin cells of the adrenal medulla that produces the 
catecholamines epinephrine and norepinephrine in variable amounts (1). When similar tumors arise 
from extraadrenal chromaffin cells they are termed paragangliomas and produce mainly 
norepinephrine and sometimes dopamine.  
Hypertension in patients with pheochromocytoma and paraganglioma (PPGL) is considered to mainly 
result from the vasopressor effects of increased circulating concentrations of norepinephrine and 
epinephrine. Steroids such as aldosterone and cortisol that originate from the adrenal cortex also 
increase blood pressure but by different mechanisms such as increased sodium reabsorption in the 
kidney and actions on the systemic vasculature (2).  
An impact of the adrenal cortex on adrenal medullary catecholamine synthesis is well established, 
starting with observations of over 50 years ago that adrenal synthesis of epinephrine depends on 
glucocorticoid-mediated induction of phenylethanolamine-N-methyltransferase (PNMT), the enzyme 
that converts norepinephrine to epinephrine (3). Differences in PPGLs that produce epinephrine 
versus those that produce predominantly norepinephrine have since been shown to reflect absence or 
presence of pseudohypoxia-induced blockade of glucocorticoid-mediated induction of PNMT (4). 
Although impact of adrenal cortex-derived steroids on adrenal medullary catecholamine systems is 
well established, it has also become apparent that catecholamines reversely impact steroidogenesis, 
possibly through paracrine actions (5-8). Moreover, besides short-term regulation by catecholamines 
there is also a long-term effect involving transcriptional regulation of steroid enzyme expression (9). 
It thus seems that adrenal medullary and cortical systems are intimately connected (10,11).  
The bidirectional connections between the adrenal cortex and medulla raise the question whether 
increased production of catecholamines in patients with PPGLs might influence adrenal 
steroidogenesis. We therefore hypothesized that high production of catecholamines in patients with 
PPGLs may result in alterations in adrenal cortical steroid systems. To explore this hypothesis we 




























































































patients with PPGLs compared to additional patients with primary hypertension (PHT). For additional 
comparative purposes we also included in the analysis groups of patients with primary aldosteronism 




This retrospective cross sectional observational study included 1073 participants recruited under a 
multicenter protocol (Prospective Monoamine-producing Tumor study) and a registry of the European 
Network for the Study of Adrenal Tumors (ENSAT). Five groups of patients were recruited: 
pheochromocytoma (n=182), paraganglioma (n=36), primary aldosteronism (n=461), Cushing 
syndrome (n=124) and hypertensive volunteers (n=270). Patients were enrolled from 12 European 
centers: 1. University Hospital Carl Gustav Carus Dresden, Germany; 2. University Hospital of 
Munich, LMU, Germany; 3. Hôpital Européen Georges Pompidou, Unité d’hypertension, Paris, 
France 4. Hôpital Cochin, Service d'endocrinologie, Paris, France; 5. Cardiovascular Research Center 
INSERM, Paris; 6. University Hospital of Turin; 7. Institute of Cardiology, Warsaw, Poland 8. 
University Hospital of Würzburg, Germany; 9.University Medical Centre Schleswig-Holstein, 
Lübeck, Germany; 10.  Radboud University Medical Centre, Nijmegen, the Netherlands; 11. 
University Hospital of Padova; 12. University Hospital Galway. Diagnosis was based on results of 
conventional diagnostic testing following current guidelines (12-14). All study protocols under which 
patients were recruited were approved by the local ethics committee of each participating center and 





























































































Plasma steroid profiling 
All blood samples for plasma steroid profiling were collected in the morning (08:00-11:00) into blood 
tubes containing lithium heparin or EDTA. Separated plasma was stored at -80°C until the steroid 
profile was analyzed by LC-MS/MS. All measurements of steroids were performed at a single 
laboratory in Dresden. The panel included 15 steroids: cortisol, 11-deoxycortisol, 21-deoxycortisol, 
corticosterone, 11-deoxycorticosterone, aldosterone, 18-oxocortisol, 18-hydroxycortisol, cortisone, 
progesterone, 17-hydroxyprogesterone, pregnenolone, androstenedione, dehydroepiandrosterone 
(DHEA) and DHEA-sulfate (DHEAS). Full details of the method, including the assay performance 
characteristics have been described elsewhere (15). 
Plasma steroid profiling before and after adrenalectomy 
Among the patients with PPGLs, additional plasma samples were available from 100 patients at an 
interval between 12 and 36 months after surgical removal of tumors (88 with pheochromocytoma and 
12 with paraganglioma). Thus, steroid profiles for these patients were obtained in paired samples of 
plasma at screening before surgical intervention and then again after resection of catecholamine-
producing tumors.   
Catecholamines and Metanephrines  
Biochemical measurements of urinary catecholamines and catecholamine metabolites (metanephrine, 
normetanephrine) in both urine and plasma were performed at a single laboratory in Dresden using 
LC-MS/MS as described previously (16,17). Details for blood and urine collections and reference 
intervals have been described in detail elsewhere (18). 
Statistical analysis   
Statistical analyses were carried out using JMP statistics software package (SAS Institute Inc, Cary, 
NC). Due to non-normal distribution of data the non-parametric Kruskal-Wallis and the Steel-Dwass 
all pairs tests were used for comparisons involving multiple groups. Spearman’s rank correlation was 
used to assess significance of relationships. Significance was defined as P<0.05. Reference intervals 




























































































first logarithmically transformed to normalize distributions and corrected for age and sex using a 
multivariate model. Multivariate analysis with age and sex as covariates was then carried out to 
establish significance between groups using the Tukey HSD post-hoc test. Final display of data was 
achieved from the exponents of least square means to derive geometric means with respective plus 
and minus standard errors as described elsewhere (20). Within group changes from pre- to post 
adrenalectomy were calculated using the Wilcoxon signed rank test. The steroids of interest are 
represented as mean of percentage (%) change with 95% confidence interval (CI), calculated after 
logarithmic transformation of the fold change and the results re-transformed (antilog) as 
percentages.  Graphics were designed using PRISM 8 (Version 8.2.1). 
 
Results  
Patient characteristics  
There were equal distributions of sexes in all groups except for patients with Cushing syndrome, in 
whom the proportions of females were higher (P<0.0001) at 77% than in the other four groups in 
whom proportions varied from 41-56% (Table 1). Patients with paraganglioma were younger 
(P<0.05) than those with pheochromocytoma and primary aldosteronism.  
Plasma steroids 
As shown in table 2, plasma concentrations of cortisol, 11-deoxycortisol, corticosterone and 11-
deoxycorticosterone were all higher (P<0.05) in patients with pheochromocytoma than in primary 
hypertensives. In contrast, 18-hydroxycortisol, DHEAS, androstenedione, pregnenolone and 
progesterone were lower (P<0.05) in patients with pheochromocytoma compared to primary 
hypertensives. There were also differences between patients with pheochromocytoma and 
paraganglioma, in who plasma concentrations of cortisol (P=0.0010), 11-deoxycortisol (P= 0.032) and 
corticosterone (P= 0.015) were higher in those with adrenal than extra-adrenal tumors. DHEA and 





























































































To account for potential confounding influences of age and sex, we used multivariate analysis to 
clarify and correct for potential impacts of these variables on the aforementioned differences in 
plasma steroids between the five groups of subjects- supplemental table 1 (21). This analysis showed 
negative relationships (P<0.01) of age with all steroids except 18-hydroxycortisol and 21-
deoxycortisol. There were also variable sex differences, which were particularly pronounced for 
DHEAS, 17- hydroxyprogesterone and progesterone (P<0.001).  
With multivariate corrections for age and sex, including generation of least square means and post hoc 
analyses using the Tukey HSD test, most of the differences observed for the data in table 2 were 
maintained or new differences realized (Figure 1). In particular, patients with pheochromocytoma 
showed higher (P<0.05) plasma concentrations of cortisol, 11-deoxycortisol, corticosterone and 11-
deoxycorticosterone than primary hypertensives. In contrast, patients with pheochromocytoma 
showed lower (P<0.05) plasma concentrations of androstenedione and DHEAS than primary 
hypertensives.  
To put the findings on steroids in PPGL patients in perspective, we also describe patients in who 
altered steroid synthesis is the primary culprit for their disorder (i.e. patients with hypercortisolism 
and primary aldosteronism). Patients with Cushing syndrome were distinguished from other groups by 
elevated (P<0.05) plasma cortisol, 11-deoxycortisol and corticosterone, whereas patients with primary 
aldosteronism were characterized by markedly elevated (P<0.05) plasma concentrations of 
aldosterone and 18-oxocortisol compared to all other groups (Figure 1). Patients with primary 
aldosteronism and Cushing syndrome both showed similarly higher (P<0.05) plasma concentrations 
of 11-deoxycorticosterone and 18-hydroxycortisol compared to primary hypertensives and 
pheochromocytoma. Patients with pheochromocytoma and primary aldosteronism showed similarly 
increased (P<0.05) plasma concentrations of 11-deoxycortisol and corticosterone above 
concentrations in primary hypertensives. However, while cortisol was higher (P<0.05) in patients with 
pheochromocytoma than those with primary aldosteronism, 11-deoxycorticosterone was higher 




























































































showed higher concentrations in primary hypertensives than other groups, there were no other steroids 
remarkably higher in this group than others.  
Similar to the differences with primary hypertensives, patients with pheochromocytoma showed 
higher (P<0.05) plasma concentrations of cortisol, 11-deoxycortisol and corticosterone than patients 
with paraganglioma (Figure 2). There were no other significant differences in measured plasma 
steroids between these two groups of patients (data not shown). 
Pre- and post-operative differences in steroids 
Following adrenalectomy, patients with pheochromocytoma presented with decreases in several 
steroids (Figure 3): cortisol, 11-deoxycortisol, 11-deoxycorticosterone, aldosterone, 18-oxocortisol 
(P<0.0001) and corticosterone (P=0.0002). In contrast, DHEA, androstendione, DHEAS, 18-
hydroxycortisol were not decreased. Pre- to post-surgical changes in steroids were present only in 
patients with pheochromocytoma. Patients operated for paraganglioma (12 patients) showed no post-
operative decreases in steroids, except cortisone (P= 0.0186) (results not shown). 
Indices of catecholamine excess in patients with pheochromocytoma and paraganglioma 
Urinary outputs of norepinephrine were not significantly different between patients with 
paragangliomas and pheochromocytoma (Table 3). In contrast, and as further explained in the 
supplement (21), urinary outputs of normetanephrine, metanephrine and epinephrine and plasma 
concentrations of normetanephrine were lower in patients with paraganglioma than 
pheochromocytoma.  
Relationships of plasma steroids with indices of catecholamine excess  
Among patients with pheochromocytoma, plasma concentrations of 11-deoxycorticosterone and 
corticosterone were positively (P<0.02) related with urinary norepinephrine, the summed total of 
urinary catecholamines (i.e., norepinephrine and epinephrine) as well as plasma and urinary free 
normetanephrine and summed total metanephrines (i.e. normetanephrine and metanephrine) in both 
plasma and urine (Table 4). Weaker relationships were observed for cortisol and 11-deoxycortisol; the 




























































































as urinary catecholamines. In contrast, 11-deoxycortisol was only positively (P<0.01) related to 
urinary normetanephrine and summed totals of urinary metanephrines. There were no relationships 
between metanephrine and epinephrine with any of the steroids. Furthermore, for patients with 
paragangliomas there were no significant relationships of any steroid with any of the various 
measures of catecholamine excess (results not shown). 
  
Discussion  
This study presents novel data establishing increased circulating glucocorticoids in patients with 
pheochromocytoma but not paraganglioma. Among the steroids that were increased in patients with 
pheochromocytoma, 11-deoxycortisol, 11-deoxycorticosterone and corticosterone showed larger 
relative increases compared to cortisol; this pattern has also been observed in clinical and subclinical 
Cushing syndrome where the same steroids provide larger diagnostic signals than cortisol (20,22).  
Moreover, positive relationships were also observed between several glucocorticoids and plasma and 
urinary markers of catecholamine excess, thus supporting in a clinical setting the concept advanced 
from preclinical studies by Ehrhart-Bornstein and Bornstein of bidirectional relationships between 
catecholaminergic and steroidal systems (11,23,24). 
Although isolated cases of pheochromocytoma in association with Cushing Syndrome have been 
described, these have involved patients with ectopic ACTH secreting pheochromocytoma. (25-27). 
These patients presented with both clinical signs of Cushing syndrome and biochemically proven 
hypercortisolism. Cases of subclinical Cushing in patients with pheochromocytoma have also been 
noted (28-30). This could be of importance, especially pre- and postoperatively, as severe 
hypoglycemia has been described post-operatively in one of those cases (30). Although hypoglycemia 
is a frequent post-operative complication in patients with pheochromocytoma, commonly thought to 
reflect the abrupt post-resection fall in circulating catecholamines (31), it is possible that post-
operative changes in glucocorticoids could also be a complicating factor. In this context, it was 
important to investigate whether plasma glucocorticoid levels decrease after successful surgery. As 
we have shown, there was a significant decrease in glucocorticoids as well as mineralocorticoids after 




























































































there were no post-operative decreases in plasma concentrations of adrenal androgens, suggesting that 
there was at least post-operative compensation of the zona reticularis in the remaining adrenal.  
The findings that only patients with pheochromocytoma and not paraganglioma showed increased 
circulating concentrations of glucocorticoids and that positive relationships of glucocorticoids to 
indices of catecholamine excess were only observed for patients with pheochromocytoma suggests 
that it is the locally produced and not the circulating catecholamines that are responsible for the effect. 
Since metanephrines are produced by metabolism of catecholamines within tumor cells, the more 
consistent and stronger positive relationships of metanephrines than catecholamines with circulating 
glucocorticoids also supports a more likely impact of locally derived rather than circulating 
catecholamines as the driver responsible for the increases in circulating glucocorticoids. Nevertheless, 
this cannot be firmly established by the present study. It remains possible that there is some influence 
of circulating catecholamines that might increase adrenal steroidogenesis in a non-paracrine fashion. 
Alternatively, the positive relationships between indices of catecholamine excess and increased 
plasma concentrations of steroids might be indirectly related by way of other mechanisms.  
We further cannot discriminate between a direct effect of catecholamines on steroid synthesis and an 
indirect effect mediated through adrenocorticotrophin (ACTH) since we have no data about the latter. 
Nevertheless, since sustained suppression of ACTH results in reductions of circulating DHEAS (32) 
the low plasma concentrations of DHEAS in patients with pheochromocytoma appear to be 
inconsistent with an influence in patients with pheochromocytoma mediated by ACTH. Apart from 
low ACTH and DHEAS in patients with adrenal Cushing syndrome, other forms of glucocorticoid 
excess such as subclinical Cushing and primary bilateral macronodular hyperplasia are also associated 
with reduced plasma concentrations of DHEAS (20,33-35). Thus, since DHEAS is responsive to 
ACTH, the lowered plasma concentrations of DHEAS might reflect lower plasma concentrations of 
ACTH, which may result from feedback inhibition of steroids on the hypothalamo-pituitary adrenal 
axis. Although some animal studies have suggested that catecholamines can directly stimulate ACTH 
secretion (36), this has not been confirmed in humans (37) and there is thus no evidence to implicate 




























































































As with any endogenous compound measured in plasma, circulating concentrations of steroids reflect 
both their entry into the circulatory compartment and their clearance from that compartment. Thus, it 
is conceivable that the elevated plasma concentrations of glucocorticoids in patients with 
pheochromocytoma, rather than reflecting increases in their production might reflect decreased 
circulatory clearance. Cortisol has a particularly slow plasma clearance, in part due to the high 
proportion of the steroid that is bound to transcortin; thus, it is possible that differences in binding to 
transcortin could also decrease the clearance of glucocorticoids and through this action increase 
plasma concentrations. Nevertheless, as further detailed in the supplement (21) it seems unlikely that 
the higher plasma concentrations of glucocorticoids, lower concentrations of DHEAS and unchanged 
concentrations of most other steroids in patients with pheochromocytoma could reflect divergent 
effects on clearance or protein-binding rather than an effect on production.  
Although elevated plasma concentrations of the three glucocorticoids - cortisol, 11-deoxycortisol and 
corticosterone – in patients with pheochromocytoma were nowhere close to the higher concentrations 
in patients with Cushing syndrome, they were similar, or even higher in the case of cortisol, to 
concentrations in primary aldosteronism. Of relevance to these findings are those of Arlt et al (38), 
who showed using mass spectrometry-based urinary steroid profiling that patients with primary 
aldosteronism were characterized by increased urinary outputs of not only free cortisol, but also 
tetrahydro-11-deoxycorticosterone and tetrahydrocortisone. The latter two steroid metabolites are 
respectively produced from 11-deoxycorticosterone and corticosterone. Thus, the present findings in 
plasma support the earlier findings in urine. As further detailed in the supplement (21), lack of 
increase in plasma cortisol in the present study, but increased urinary free cortisol in the earlier study 
of Arlt et al (38) is easily explained by the inferiority of morning plasma cortisol compared to the 
other three plasma corticosteroids and urinary free cortisol for assessing hypercortisolism. Since 
production of excess cortisol in primary aldosteronism is now recognized as a potential contributing 
factor to the excess morbidity of primary aldosteronism (39,40), it seems possible that the same may 




























































































The strengths of this study include the multicenter inclusion of a large number of patients with 
different forms of adrenal hypertension as well as large numbers of primary hypertensives. One 
limitation, in addition to the aforementioned lack of data on ACTH, relates to lack of measurements 
of 24 hr urinary free cortisol. Also, we had a high proportion of females in the group with Cushing 
syndrome, as is expected in such patients (41). Although we used multivariate analyses to correct for 
such influences, it remains possible that this may have been insufficient for some comparisons. 
Nevertheless, such differences along with the sex imbalance in the patients with Cushing syndrome 
are not relevant to the higher plasma concentrations of glucocorticoids and aldosterone in patients 
with PPGLs compared to hypertensive groups.    
Pheochromocytomas are among the most life-threatening of all endocrine diseases, with elevated 
morbidity and mortality, especially if undiagnosed. The diagnosis represents a challenge, due partly to 
lack of specificity of most clinical signs and symptoms. The cardiovascular complications are mainly 
secondary to excessive secretion of catecholamines from tumors. However, the present data raises the 
possibility that glucocorticoids might also contribute to the cardiovascular and metabolic 
complications caused by pheochromocytomas. This supports the concept that altered steroid 
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 Figure legends 
Figure 1. Plasma concentrations for 12 steroids of the 15 steroid panel in patients with 
pheochromocytoma compared to primary hypertensives and patients with Cushing syndrome and 
primary aldosteronism. Values of steroids are shown as least square means corrected for age and sex 
and calculated from exponents of logarithmically transformed data (geometric means) with standard 
errors.  
Figure 2. Plasma concentrations for three glucocorticoids in patients with pheochromocytoma 
compared to those with paraganglioma. Values are shown as least square means corrected for age and 
sex and calculated from exponents of logarithmically transformed data (geometric means) with 
standard errors. 
Figure 3.  Pre- to post-operative differences in plasma concentrations of 11 steroids after 
adrenalectomy in patients with pheochromocytoma. Differences in the steroids of interest are shown 
as geometric means of percentage (%) changes with 95% confidence intervals (CI). Means and 
confidence intervals were calculated after logarithmic transformation of fold changes and the results 





























































































Table 1. Age and sex distribution       
Group PHT PGL PHEO PA CS 
N 270 36 182 461 124 
Sex (F/M) 120/150 17/19 109/73 188/273 95*/29 
Age±SD 49.2±13.3 44.±14.4*¤‡ 50.0±15.0 51.1±10.6 48.5±15.5 

































































































Table 2 Plasma concentrations of 15 adrenal steroids in the reference group (PHT) compared to 
patients with paraganglioma (PGL), pheochromocytoma (PHEO), primary aldosteronism (PA) and 
Cushing Syndrome (CS) 
Reference Group Endocrine hypertension  
Plasma steroids (nmol/L) PHT PGL PHEO PA CS 
Cortisol  257 248 338***§¥ 317***§ 496***† 
  (205-341)  (213-378) (259-452) (227-412) (390-636) 
11-Deoxycortisol 0.47 0.47 0.86***§¥ 0.88***§ 1.53***† 
 (0.29-0.71) (0.29-0.93)  (0.45-1.55) (0.54-1.61) (0.86-2.85) 
21-Deoxycortisol 0.035 0.029 0.043 0.066***§¥£ 0.052*§¥ 
 (0.017-0.069) (0.017-0.049) (0.020-0.089) (0.028-0.188) (0.020-0.121) 
Aldosterone 0.121 0.127 0.142 0.354***† 0.093 
 (0.068-0.190) (0.060-0.219) (0.063-0.260) (0.201-0.610) (0.034-0.239) 
Corticosterone 4.70 4.20*‡  6.97***§¥ 6.61***§ ¥ 10.29***§¤*¥‡ 
 (3.05-8.41) (2.72-7.38) (4.19-11.82) (3.62-12.15) (6.28-17.42) 
11-Deoxycorticosterone 0.102 0.154*§ 0.196***§ 0.218*§¥‡ 0.207***§ 
 (0.052-0.184) (0.096-0.223) (0.098-0.281) (0.146-0.345) (0.134-0.383) 
18-Oxocortisol 0.022 0.027 0.027 0.053***† 0.030 
 (0.013-0.037) (0.016-0.069) (0.016-0.058) (0.026-0.230) (0.011-0.047) 
18-Hydroxycortisol 1.60 1.26*§ 1.34*§ 2.12***§¥‡ 2.16***§¥‡ 
 (1.11-2.28) (0.83-1.66) (0.89-1.98) (1.28-4.01) (1.21-3.53) 
Cortisone 49.52 49.09 52.98 49.11*‡ 55.70*§¤ 
 (42.93-58.61) (42.50-62.85) (44.05-62.69) (39.12-59.23) (42.67-70.02) 
DHEA 8.37 11.88*§ 8.40*¥ 7.76*¥ 6.25 
 (5.30-13.90) (6.73-19.59) (4.14-13.32) (4.19-12.5) (2.03-15.98) 
DHEA-SO4(micomol) 8.31 7.63 4.09***§¥ 5.41*§ 5.82 
 (4.61-12.00)  (4.80-9.27) (2.24-7.78) (3.24-8.48) (1.45-13.80) 
Androstenedione 2.97*£ 2.32 2.23***§ 2.69*‡ 3.83*†  
 (2.19-4.15) (1.85-2.98) (1.51-3.19) (1.78-4.03) (1.95-7.73) 
Pregnenolone 3.75 3.89 3.17***§ 2.12*§¥ 4.69 *¤ 
 (2.41-6.01) (1.77-8.27) (1.09-5.70) (0.66-6.29) (1.27-10.00) 
17-Hydroxyprogesterone 1.70 1.93 1.41 2.01***§‡ 1.41*¤ 
 (0.58-2.60) (1.16-3.28) (0.65-2.47) (1.05-3.05) (0.74-2.71) 
Progesterone 0.25 0.23 0.12***† 0.25***‡ 0.23*‡ 
 (0.18-0.36) (0.07-0.48) (0.05-0.23) (0.13-0.50) (0.08-0.51) 
Plasma concentrations are shown as medians in nmol/L , the 25th and 75th quartiles in paranthesis  * P< 0.005, *** 
P<0.0001,  §different than PHT, ¥ different thn PGL, 
‡
 different than PHEO, £different than CS, ¤different than 




























































































Table 3: Twenty-four hour urinary outputs of catecholamines and metanephrines and plasma concentrations of 
metanephrines in patients with pheochromocytoma compared to paraganglioma 
  Pheochromocytoma   Paraganglioma P-value 
n=183 n=35 
Urinary NE (nmol/day) 472 (231-1255)¥ 388 (175-977)§ NS 
Urinary E (nmol/day) 98 (21-394) 18 (9-28) <0.001 
Urinary NMN (nmol/day) 1332 (523-3387)¥ 538 (225-1543)§ 0.0119 
Urinary MN (nmol/day) 534 (94-1761) 86 (51-104) <0.0001 
Plasma NMN (nmol/L) 4.26 (1.55-10.7) 2.27 (0.88-6.18) 0.0278 
Plasma MN (nmol/L) 0.92 (0.17-2.96) 0.17 (0.13-0.22) <0.0001 
Abbreviations: NE, norepinephrine; E, epinephrine; NMN, normetanephrine; MN, metanephrine; NS, not significant. Results are shown as 
medians and interquartiles (25th and 75th); the significance for differences were assessed using Wilcoxon sum ranked-test and are shown 
































































































Table 4: Relationships of plasma steroid concentrations with plasma and urinary metanephrines and urinary 
catecholamines in patients with pheochromocytoma 
cortisol 11-deoxycortisol 11-deoxycorticosterone corticosterone 
    rs p rs p rs p rs p 
Plasma metanephrines 
  NMN 0.1326 0.0744 0.0730 0.3271 0.2171 0.0032 0.1830 0.0134 
  NMN+MN 0.1874 0.0113 0.0869 0.2436 0.1916 0.0096 0.2170 0.0033 
Urinary free metanephrines         
  NMN 0.1487 0.0754 0.2166 0.0091 0.3472 <0.0001 0.2869 0.0005 
  NMN+MN 0.1907 0.0216 0.2253 0.0064 0.3273 <0.0001 0.3160 0.0001 
Urinary catecholamines              
  NE 0.1592 0.0575 0.1187 0.1579 0.2840 0.0006 0.2089 0.0123 
  NE+E 0.2101 0.0118 0.1371 0.1026 0.2589 0.0018 0.2426 0.0035 
Relationships are shown for NMN and NE as well as the sums of both NMN and MN or NE and E according to Spearman's rank 






















































































































































































































































































































Figure 1. § P< 0.05 different than primary hypertension, ‡ different than pheochromocytoma, £ different than Cushing syndrome, 









































Figure 1. Results of the steroid panel in patients with pheochromocytoma compared with patients with other 






































































































































Figure 2. Results of the steroid panel in patients with pheochromocytoma compared 


















































































Figure 3. Decrease in steroids after adrenalectomy in pheochromocytoma patients  
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